Table 6. Summary of studies assessing the prognostic value of cyclin D1 in OTSCC providing unadjusted or adjusted estimates of HR and their 95% confidence intervals for one or more endpoints, the HRs contrasting positive to negative expression.

(Authors, Year) Country	Stage or tumour size (primary treatment)	Primary antibody	Cutoff point in percentage	No. of cases	No. of Positive cases (%)	Endpoint	Unadjusted analysis	Adjusted analysis	Compliance to REMARK guidelines
(Bova et al, 1999) Australia	I–IV (S in 96 patients; S with adjuvant RT in 52 patients)	NCL-cyclin D1-GM, monoclonal (1 : 50; Novocastra, Rockdale, Australia)	10	147	100 (68)	OS	HR 3.89 (95% CI 1.37–11.07), P=0.01	HR 4.2 (95% CI 1.23–14.09), P=0.02	Fulfilled items summarised in Table 1
						DFS	HR 2.50 (95% CI 1.32–5.15), P=0.006	HR 2.48 (95% CI 1.0–6.15), P=0.05
(Trivedi et al, 2011) India	T1–T4 (S followed by RT in 26 cases, CT in 1 case, RT with CT in 5 cases)	P2D11F11, monoclonal, (dilution 1 : 50; Novocastra laboratories, Newcastle, UK)	10	61	25 (41)	OS	HR 2.20 (95% CI 0.85–5.70) P=0.103	NA	Checklist no. 5 was not fulfilled
						RFS	HR 1.91 (95% CI 0.84–4.38), P=0.122	NA

Abbreviations: CI=confidence interval; CT=chemotherapy; DFS=disease-free survival; HR=hazard ratio; NA=not available; OS=overall survival; RT=radiotherapy; RFS=relapse-free survival; S=surgery.